Remarkable Efficacy of Capmatinib in a Patient with Cancer of Unknown Primary with MET Amplification
Authors:
Open Access
- 1 December 2025
- journal article
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 64 (23) , 3460-3464
Abstract
This case report describes a 70-year-old female with cancer of unknown primary origin (CUP) who exhibited multiple distant lymph node metastases. Despite conventional chemotherapy (carboplatin and paclitaxel) and immunotherapy (nivolumab), disease progression was noted. Genomic profiling revealed MET amplification, leading to the administration of capmatinib, a selective MET tyrosine kinase inhibitor. The patient experienced substantial tumor reduction with dose adjustments due to adverse effects, indicating the potential efficacy of capmatinib in treating CUP with MET amplification.Keywords
This publication has 9 references indexed in Scilit:
- Diagnosis and treatment of non-small cell lung cancer (NSCLC) harboring MET Ex14 skipping: have we met the desired drug?Translational Lung Cancer Research, 2024
- Progress report of a cross‐organ and biomarker‐based basket‐type clinical trial: BELIEVE TrialCancer Science, 2023
- Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung CancerNew England Journal of Medicine, 2020
- The currently declining incidence of cancer of unknown primaryCancer Epidemiology, 2019
- Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2019
- Cancer of unknown primary—Epidemiological trends and relevance of comprehensive genomic profilingCancer Medicine, 2018
- MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor PrognosisClinical Cancer Research, 2016
- Targeting MET Amplification as a New Oncogenic DriverCancers, 2014
- MET mutations in cancers of unknown primary origin (CUPs)Human Mutation, 2010